-+ 0.00%
-+ 0.00%
-+ 0.00%

BD Receives FDA 510(k) Clearance For Advanced Microbiology Solution

Benzinga·04/09/2025 20:22:16
Listen to the news

Integration of BD Phoenix™ Automated Microbiology System, BDXpert™ System and BD Synapsys™ Informatics Solution Supports Accurate Detection of Antimicrobial Resistance

FRANKLIN LAKES, N.J. (April 9, 2025) – BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for BD Phoenix™ M50 and BDXpert™ System on the BD Synapsys™ Informatics Solution, leveraging rapid identification (ID) and antimicrobial susceptibility testing (AST) algorithms to assist in the interpretation of complex diagnostic data to help ensure accurate and reliable diagnoses related to antimicrobial resistance (AMR).